Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Genomatica develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability, and performance. Genomatica has earned widespread acclaim for its technology; has commercialized processes for the chemical butanediol (for biodegradable plastics and apparel) and for butylene glycol (cosmetics and personal care), and is working on bio-nylon. Awards include the Kirkpatrick Award, for “the most noteworthy chemical engineering technology commercialized in the world” and the ICIS Innovation Award for its Brontide(TM) butylene glycol.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as obesity, diabetes, and inflammatory stress. The company has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents. NuSirts first product, NS-0100, uses NuSirts platform technology to combine the natural product leucine with a very low dose of metformin for the treatment of type II diabetes. Although, metformin is the gold standard in the treatment of early-type II diabetes many patients can not tolerate the adverse gastrointestinal side effects metformin can cause in some patients. The company is currently testing varying doses of NS-0100 in Phase 2 clinical study to find the most efficacious dose of this new combination. If NuSirts clinical trials are successful NS-0100 may offer patients a viable alternative to metformin. NuSirt has filed eleven patent applications (two of which have been issued) and completed four clinical and numerous pre-clinical studies based on the patented technologies.

Develops technology to uncover molecular and genetic diversity in microorganisms that can not be cultured in the laboratory

Danisco US, Inc. manufactures synthetic resins, synthetic rubbers and industrial chemicals. The company is headquartered in Wilmington, DE.

Cybele Microbiome offers a proprietary platform that brings precision control to the microbiome. Its AI platform combines machine learning with cutting-edge biotechnology and proprietary data sources, to discover natural prebiotics that feeds the microbiome to make targeted natural solutions.

REMD Biotherapeutics, Inc. is a private company headquartered in Camarillo, CA. The firm discovers and develops cutting-edge bio-medicines to treat cancer, diabetes and other diseases. It was founded in 2011 by Yan Hai and Tom Boone. Yan Hai has been the CEO since then.\nThe company says this about itself: REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing, China (Beijing CoSci-REMD Bio Med-Tech Co, Ltd). REMD Bio��s lead product candidate, volagidemab (REMD-477), a fully human antibody to the glucagon receptor licensed from Amgen in 2013, is presently in clinical studies for treatment of diabetes as well as in preclinical studies for treatment of other metabolic disorders. REMD Bio��s discovery research leverages extensive expertise in generating and developing therapeutic antibodies to G protein-coupled receptors (GPCRs) as well as to other multi-transmembrane cell surface antigens.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. The company engages in synthesizing and programming DNA in developing and utilizing the technologies in synthetic genomics. It designs and develops microbes for industrial processes and environmental applications. The company also develops microbial cultivation technologies and monitoring approaches that reveal novel microorganisms, suites of new genes, and fermentation platforms for the metabolic engineering of microbes for commercial Bioenergy applications. In addition, it involves in designing advanced biofuels with properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value-added products directly from sunlight and carbon dioxide; developing new biological solutions to enhance production and/or recovery rates of subsurface hydrocarbons; and developing high-yielding, disease resistant, and economic feedstocks. The company's solutions help in improving the production of energy, chemicals, and pharmaceuticals, as well as enabling carbon sequestration and environmental remediation.

Jasco Pharmaceuticals, LLC is a privately held, pre-clinical stage biopharmaceutical company focused on the development of small molecule oncology therapeutics. Jasco was founded with a core expertise in high speed medicinal chemistry providing a launching point for a chemical genomics approach to the discovery of selective protein kinase inhibitors. The company’s vision is to rapidly and effectively develop pre-clinical oncology candidates that are then guided through the clinical development process by means of strategic partnerships.

Part of Southern Medical University, Zhujiang Hospital of Southern Medical University is a company headquartered in Guangzhou, China, that operates hospital.

The world they live in is built from petroleum. The paints on their walls, the carpets in their homes, the tires on their cars, the plastics for everyday consumer goods – these and many more products are made from chemicals that are mostly made from petroleum, creating a $3 trillion/yr industry. To fulfill their dependency on petroleum, they do crazy things like setting up oil rigs in the middle of the ocean and drilling several miles into the ocean floor! They’ve done these things because they have had no alternative to meet their needs. Not anymore! Over the past decade, advances in engineering microorganisms have afforded us the opportunity to make the same chemicals that are traditionally made from petroleum. Instead of requiring raw materials buried deep within the earth, microbes can use abundant and renewable sources of carbon such as sugars during processes akin to brewing beer. Despite the numerous advantages, making chemicals this way at the industrial level is still rare. This is because it’s still more expensive than using petroleum for producing the chemicals. Although a few challenges need to be solved to usher in the era of renewable chemicals, a fundamental constraint that limits the economic competitiveness of using microbes is the loss of at least 33% of the carbon as carbon dioxide waste during the fermentation – think of this as the head on your beer. Because of this carbon loss, potential product is simply not made. In technical terms, the maximum achievable yields are 67%. As sugars are the most expensive component of a bioprocess, making the carbon dioxide waste translates to as much as 20% of total costs, which severely hampers the economics of the bioprocess and its competitiveness with petroleum-based production methods. At ZymoChem, they are re-imagining the microbe, one that is designed to eliminate (or substantially reduce) carbon loss during the production of chemicals. To do this, they had to design a completely new biosynthetic pathway – one that doesn’t exist in nature – to make the chemicals. Each individual step of this pathway is designed to not lose carbon as carbon dioxide, enabling their biosynthetic pathway to retain all of the sugar’s carbon into the final chemical product. This carbon conservation allows their approach to have superior theoretical yields, up to 50% better than existing state-of-the-art technology! In turn, their technology has the potential to substantially lower production costs and drastically improve cost-competitiveness for making a variety of chemicals from renewable sources, even at today's oil prices.

Guangzhou Jiankun Biotechnology Co., Ltd., established on 2011-10-26, Business scope includes biotechnology development services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Import and export(Excluding franchised products);Technology Import and Export;Commodity wholesale trade(Except for licensed and approved products);Commodity retail trade(Except for licensed and approved products);Retailing of cosmetics and hygiene products;Wholesale of cosmetics and hygiene products;

US Agriculture LLC provides investment services. It operates and manage farmland assets and portfolios, develop and implement farmland investment strategies, underwrite and acquire farmland assets across a variety of regions and crop types, develop and implement efficient and effective reporting processes, design and implement investment policies, develop and implement asset allocation strategies, create and implement tools for market and asset targeting, and create and implement portfolio optimization tools and processes. The company was founded in 2015 and is headquartered in Indianapolis, IN.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA.

Guangzhou Zhitech Biotechnology Co., Ltd., established on 1998-10-12, Business scope includes agricultural scientific research and experimental development;Food Additive Sales;Feed Additive Sales;Animal Husbandry and Fishery Feed Sales;Feed Raw Material Sales;Non-residential real estate leases;Food additive production;food production;food business;Feed additive production;Import and export;Technology Import and Export;feed production

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Arzeda harnesses the power of Intelligent Protein Design Technology™ - combining physics-based protein design and AI algorithms - to create and manufacture new designer proteins and enzymes that enhance our lives and protect our planet. In partnership with Fortune 500 companies and industrial leaders, we develop healthy and sustainable products for the food & nutrition, consumer products, advanced materials, and diagnostics & pharma industries globally - delivering on the promise of biotechnology